India news Live Updates, 12 October 2026: Supreme Court questions Centre on capping margins beyond anti-cancer drugs

A trade-margin cap limits how much wholesalers and retailers can add to a medicine’s maximum retail price. At 30% of MRP, the combined permitted trade margin would be restricted to that share. The MRP remains the displayed ceiling price, while the cap targets the portion earned by intermediaries.

For example, if a medicine has an MRP of Rs 100, a 30% margin would equal Rs 30. The remaining amount would cover the medicine’s underlying price and other components. The article does not specify the exact formula or whether the limit applies separately to wholesalers and retailers.

The Centre has already limited margins on anti-cancer drugs to 30% of MRP. The Supreme Court questioned why a similar approach could not cover all medicines. It asked the government to submit modalities for broader medicine-price regulation by October 27, but no wider cap had been announced in the article.

The 30% trade-margin cap currently applies to anti-cancer drugs. The measure was introduced to limit the amount added by sellers and reduce what patients pay for these medicines. The article presents it as a targeted policy rather than a rule covering every medicine.

The Supreme Court questioned why the Centre could not apply a similar cap across all medicines. Its concern was that patients may still face steep markups on other medicines and on medical devices. The court said the government’s response offered little benefit to patients, according to the report.

The broader proposal remains under consideration. The bench of Justices Vikram Nath and Sandeep Mehta asked the Centre to submit modalities for regulating medicine prices by October 27. The article does not say that the government has already agreed to cap margins on all medicines.

The government has estimated that limiting trade margins on anti-cancer drugs could save patients around Rs 2,500 crore annually. This figure represents the expected reduction in the amount patients collectively spend because sellers’ margins are restricted.

The article links the projected savings to the 30% cap on MRP. By limiting the trade margin, the policy aims to reduce steep markups between the medicine’s supply chain and the price paid by patients. The report does not provide a calculation for each individual drug or patient.

The estimate concerns anti-cancer drugs only. It does not state how much patients might save if the same policy covered every medicine. The Supreme Court’s request for broader regulatory modalities could lead to further discussion, but the article gives no final decision or additional savings estimate.

Capping trade margins across all medicines could reduce the amount added by wholesalers and retailers. If those savings reached consumers, patients could pay less at pharmacies. This matters because the Supreme Court flagged steep markups on medicines and medical devices.

For example, a medicine with a high retail price could become cheaper if the permitted trade margin were limited to a fixed share of its MRP. The mechanism would work by restricting the difference between the supply-chain price and the amount charged to patients. The article does not provide a general savings figure.

The result would depend on the final rules, including which products are covered and how compliance is monitored. The Centre has been asked to submit regulatory modalities by October 27. Until then, broader savings remain possible rather than guaranteed, and the current confirmed estimate applies only to anti-cancer drugs.

Trade margins are the amounts earned by intermediaries as medicines and medical devices move through the distribution chain. They matter because these additions contribute to the final price patients see and pay. Larger margins can mean higher retail prices, especially when the underlying product is already costly.

A simple example is a medicine whose price rises as wholesalers and retailers add their permitted earnings. A cap limits that addition to a specified share of MRP. The article identifies anti-cancer drugs as one area where margins have been limited to 30%, while also flagging steep markups on other medicines and medical devices.

The article does not detail every component of a medicine’s price or explain the separate margins of each seller. However, it shows why trade margins are central to the policy debate. The Supreme Court said the government’s response offered little benefit to patients and asked for broader regulation plans.

The Supreme Court’s role here is to examine the government’s response to concerns about medicine prices. By questioning the Centre, the bench is testing whether the existing policy adequately protects patients. It is not described as directly setting every medicine’s price.

The bench of Justices Vikram Nath and Sandeep Mehta focused on the government’s decision to cap anti-cancer drug trade margins at 30% of MRP. It asked why a similar limit could not apply to all medicines. The court also flagged steep markups on medicines and medical devices and said the response offered little benefit to patients.

The court then asked the Centre to submit modalities for regulating medicine prices by October 27. This makes the government responsible for presenting a workable regulatory approach. The article does not say what the final rules will be or whether the court will order a universal cap.

Medicine-price regulation seeks to protect patients from unaffordable prices while allowing medicines to be produced, supplied, and sold. A margin cap addresses the amount earned by intermediaries. A workable policy must also account for the costs involved in making and distributing medicines. The article does not set out the government’s full balancing framework.

The 30% cap on anti-cancer drug margins illustrates one approach. It limits the trade share of MRP and is expected by the government to save patients around Rs 2,500 crore annually. At the same time, the policy concerns the trade margin rather than every cost associated with producing a drug.

The Supreme Court wants the Centre to explain whether similar regulation can cover all medicines. Its request reflects concern over steep markups and limited patient benefit. The Centre’s modalities, due by October 27, are expected to clarify how broader controls could work, but the article gives no final design.